These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29069110)

  • 21. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
    Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial.
    Green SM; Donegan E; Frey BN; Fedorkow DM; Key BL; Streiner DL; McCabe RE
    Menopause; 2019 Sep; 26(9):972-980. PubMed ID: 31453958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A; Florea I; Loft H; Christensen MC
    J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
    Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
    J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
    McIntyre RS; Harrison J; Loft H; Jacobson W; Olsen CK
    Int J Neuropsychopharmacol; 2016 Jun; 19(10):. PubMed ID: 27312740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
    Mattingly GW; Necking O; Schmidt SN; Reines E; Ren H
    Curr Med Res Opin; 2023 Apr; 39(4):613-619. PubMed ID: 36884024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC; Schmidt S; Grande I
    J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder.
    Vieta E; Loft H; Florea I
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):877-884. PubMed ID: 28693903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
    Almeida SS; Christensen MC; Simonsen K; Adair M
    J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.
    Papakostas GI; Johe K; Hand H; Drouillard A; Russo P; Kay G; Kashambwa R; Hoeppner B; Flynn M; Yeung A; Martinson MA; Fava M
    Mol Psychiatry; 2020 Jul; 25(7):1569-1579. PubMed ID: 30626911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.
    Naik H; Chan S; Vakilynejad M; Chen G; Loft H; Mahableshwarkar AR; Areberg J
    Basic Clin Pharmacol Toxicol; 2016 May; 118(5):344-55. PubMed ID: 26525043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD).
    Ng CG; Abousheishaa AA; Low SY; Zainal NZ; Thong KS; Awaluddin AB; Loo TH; Yacob SB; Nik Jaafar NR; Abdul Taib NIA; Mohamad Kamal NAB; Ismail F; Zamaniah Wi W
    Asian Pac J Cancer Prev; 2023 Aug; 24(8):2583-2591. PubMed ID: 37642043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
    Cumbo E; Adair M; Åstrom DO; Christensen MC
    Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
    Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
    Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.